AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal

AstraZeneca (AZN) and Japanese partner Daiichi Sankyo announced that their antibody-drug conjugate, datopotamab deruxtecan (Dato-DXd), failed to achieve statistical significance in the final overall survival (OS) analysis in a study for a metastatic breast cancer indication.The TROPION-Breast01 phase III study evaluated Dato-DXd,a TROP2-directed ADC for treating inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer previously treated with endocrine-based therapy and at ...